Clinical trials to include Indian subjects, a welcome decision says CRO

By Flora Southey

- Last updated on GMT

(Image: Getty/Niyazz)
(Image: Getty/Niyazz)
Clinical trials conducted outside of India – which test drugs for the Indian market – must include Indian subjects, according to a ruling in India last month.

The technical committee meeting​ held on September 25, 2017, was led by the director general of health services Jagdish Prasad, and decided that “any firm intending to market a new drug which is being developed outside the country, should include Indian patients.”

In the same meeting, it was determined that trials already approved in ICH (International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use) countries, such as those in the US, Europe, and Japan, will be reviewed on priority by the Drugs Controller General of India (DCGI).

CRO perspective

The ruling will affect clinical research organisations’ (CROs) recruitment procedures for drug trials intended for the Indian market.

According to CRO George Clinical – which conducts clinical trials globally, including India – the decision will boost the effectiveness of medicines marketed in the country.

“This is an important move in determining the efficacy of drugs marketed in India,” ​said the firm’s managing director Vanaja Krishnan.

“After a series of events that impacted negatively on the sector in India in the early part of this decade, the decisions reached in the technical committee meeting reflect India’s harmonisation with international trial requirements,” ​she said.

Krishnan said the decision will encourage drug firms to include India​ in global trials. 

“It shows a reinvigoration of confidence in the clinical trials environment in India, and will encourage the inclusion of India in global trial programmes,” ​she explained.

“Global sponsors will again consider India as an important part of their research and development programme.”

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Why should you use clinical trial technology?

Why should you use clinical trial technology?

Content provided by Formedix | 01-Nov-2023 | White Paper

New, innovative clinical trial technology is helping to revolutionize the research landscape. COVID-19 demonstrated that clinical trials can be run much...

Related suppliers

Follow us

Products

View more

Webinars